Publication | Open Access

Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study

Cvd-real 2Cardiovascular EpidemiologyCardiovascular DiseaseAntihypertensive TherapyGlobal HealthCardiovascular PharmacologyPharmacotherapyPublic HealthMedicineAtherosclerosisEpidemiologyCardiovascular EventsSglt2 Inhibitors